Cargando…

1725. Differences in serotype 3 antibody response and antibody functionality compared to serotype 19A following 13-valent pneumococcal conjugate immunization in children

BACKGROUND: Background. 13-valent pneumococcal conjugate vaccine (PCV13) includes serotype 3 and 19A. However, prevention of infections with PCV13 may be less effective against serotype 3 than 19A. In young children, determine differences in IgG antibody levels, functionality of antibody by OPA and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fuji, Naoko, Pham, Minh, Kaur, Ravinder, Pichichero, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679009/ http://dx.doi.org/10.1093/ofid/ofad500.1557

Ejemplares similares

1688. Naturally-induced Serum Antibody Levels in Children to Pneumococcal Polysaccharide 15B that Correlate with Protection from Nasopharyngeal Colonization but Anti-serotype 15B Antibody has Low Functional Cross-reactivity with Serotype 15C.
por: Kaur, Ravinder, et al.
Publicado: (2023)

Comparative Immunogenicity of 7 and 13-Valent Pneumococcal Conjugate Vaccines and the Development of Functional Antibodies to Cross-Reactive Serotypes
por: Grant, Lindsay R., et al.
Publicado: (2013)

2707. Non 13-Valent Pneumococcal Conjugate Vaccine Serotypes Predominate as Causes of Pneumococcal Otitis Media in Children
por: Hulten, Kristina G, et al.
Publicado: (2019)

1100 Notable Serotype Replacement of Invasive Streptococcus pneumoniae in Kagoshima, Japan, after the Sequential Introduction of 7-valent and 13-valent Pneumococcal Conjugate Vaccines
por: Nishi, Junichiro, et al.
Publicado: (2014)

P06 The 15-valent pneumococcal conjugate vaccine (PCV) V114 induces cross-reactive antibodies against pneumococcal serotype 6C
por: Shi, Yaru, et al.
Publicado: (2023)

Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine
por: Patel, Sweta M., et al.
Publicado: (2022)

576. Burden of Pneumococcal Disease Due to Serotypes Covered by the 13-Valent and New Higher-Valent Pneumococcal Conjugate Vaccines in All Children and Children at Risk in the United States
por: Huang, Liping, et al.
Publicado: (2022)

Serotype-Specific IgG Antibody Waning after Pneumococcal Conjugate Primary Series Vaccinations with either the 10-Valent or the 13-Valent Vaccine
por: van Westen, Els, et al.
Publicado: (2018)

Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
por: Hanquet, Germaine, et al.
Publicado: (2022)

2716. Persistence of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Serotypes in Invasive Pneumococcal Disease in Adults in Southern Ontario Canada Despite Routine Pediatric Vaccination
por: McGeer, Allison, et al.
Publicado: (2019)

The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C
por: Shi, Yaru, et al.
Publicado: (2023)

1446. Correlation Between Adult Invasive and Noninvasive Streptococcus pneumoniae Disease in 13-Valent Pneumococcal Conjugate Vaccine Serotypes in the United States
por: Suaya, Jose A, et al.
Publicado: (2018)

Impact of Ten-Valent Pneumococcal Conjugate Vaccine Introduction on Serotype Distribution Trends in Colombia: An Interrupted Time-Series Analysis
por: Leal, Aura Lucia, et al.
Publicado: (2017)

Transition of Serotype 35B Pneumococci From Commensal to Prevalent Virulent Strain in Children
por: Fuji, Naoko, et al.
Publicado: (2021)

1373. Vaccine Effectiveness and Pneumococcal Serotypes in Pediatric Otitis Media in the Era of Routine 13-valent Pneumococcal Vaccination in the United States
por: Hulten, Kristina G, et al.
Publicado: (2020)

1728. Immune Responses to Cross-Reactive Serotypes 6C and 15C After 20-Valent Pneumococcal Conjugate Vaccine in Infants
por: Tamimi, Noor, et al.
Publicado: (2023)

Serotype-specific effectiveness against pneumococcal carriage and serotype replacement after ten-valent Pneumococcal Conjugate Vaccine (PCV10) introduction in Pakistan
por: Nisar, Muhammad Imran, et al.
Publicado: (2022)

Empyema due to Streptococcus Pneumoniae Serotype 9V in a Child Immunized with 13-Valent Conjugated Pneumococcal Vaccine
por: Sütçü, Murat, et al.
Publicado: (2017)

Periodic cycles of pneumococcal serotypes carried by children before and after 7-valent pneumococcal conjugate vaccine
por: Paulo, Ana Cristina, et al.
Publicado: (2017)

647. Characterization and Development of Human Monoclonal Antibodies to Pneumococcal Serotype 3
por: Babb, Rachelle, et al.
Publicado: (2018)

Serotype Distribution of Clinical Streptococcus pneumoniae Isolates before the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Cambodia
por: Inghammar, Malin, et al.
Publicado: (2018)

Post–13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children of Serotypes Included in Candidate Extended-Spectrum Conjugate Vaccines
por: Ben-Shimol, Shalom, et al.
Publicado: (2021)

Estimates of the Health and Economic Burden of Pneumococcal Infections Attributable to the 15-Valent Pneumococcal Conjugate Vaccine Serotypes in the USA
por: Owusu-Edusei, Kwame, et al.
Publicado: (2022)

Antibody enhanced HPLC for serotype-specific quantitation of polysaccharides in pneumococcal conjugate vaccine
por: Deng, James Z., et al.
Publicado: (2023)

Serotype 3 Remains the Leading Cause of Invasive Pneumococcal Disease in Adults in Portugal (2012–2014) Despite Continued Reductions in Other 13-Valent Conjugate Vaccine Serotypes
por: Horácio, Andreia N., et al.
Publicado: (2016)

1430. Evolving Impact of 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease
por: Yildirim, Inci, et al.
Publicado: (2018)

Correction to: Estimates of the Health and Economic Burden of Pneumococcal Infections Attributable to the 15-Valent Pneumococcal Conjugate Vaccine Serotypes in the USA
por: Owusu-Edusei, Kwame, et al.
Publicado: (2022)

Optimal Serotype Compositions for Pneumococcal Conjugate Vaccination under Serotype Replacement
por: Nurhonen, Markku, et al.
Publicado: (2014)

Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data
por: Strutton, David R, et al.
Publicado: (2012)

Pediatric Complicated Pneumonia Caused by Streptococcus pneumoniae Serotype 3 in 13-Valent Pneumococcal Conjugate Vaccinees, Portugal, 2010–2015
por: Silva-Costa, Catarina, et al.
Publicado: (2018)

Global Distribution of Invasive Serotype 35D Streptococcus pneumoniae Isolates following Introduction of 13-Valent Pneumococcal Conjugate Vaccine
por: Lo, Stephanie W., et al.
Publicado: (2018)

Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Severe Invasive Disease Caused by Serotype 3 Streptococcus Pneumoniae in Italian Children
por: Lodi, Lorenzo, et al.
Publicado: (2019)

2703. Pneumococcal Carriage of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Non-PCV13 Serotypes among Greek Children Vaccinated with PCV13 in a 3 + 1 Schedule During the First 6 years after the Fourth Dose of PCV13
por: Syrogiannopoulos, George A, et al.
Publicado: (2019)

Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in Korea and Hong Kong
por: Mohanty, Salini, et al.
Publicado: (2022)

Systematic Literature Review of the Epidemiological Characteristics of Pneumococcal Disease Caused by the Additional Serotypes Covered by the 20-Valent Pneumococcal Conjugate Vaccine
por: Méroc, Estelle, et al.
Publicado: (2023)

The Risk of Febrile Seizures Following Influenza and 13-Valent Pneumococcal Conjugate Vaccines
por: Baker, Meghan, et al.
Publicado: (2017)

Streptococcus pneumoniae Serotype 12F-CC4846 and Invasive Pneumococcal Disease after Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Japan, 2015–2017
por: Nakano, Satoshi, et al.
Publicado: (2020)

2711. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease in Older Adults
por: Lewis, Ned, et al.
Publicado: (2019)

7-Valent Pneumococcal Conjugate Vaccination in England and Wales: Is It Still Beneficial Despite High Levels of Serotype Replacement?
por: Choi, Yoon Hong, et al.
Publicado: (2011)

Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001
por: Leach, Amanda J, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_n4jd14mbrcvcfhd8rivfqj5gap